Block Listing 6-month review

Hikma Pharmaceuticals Plc
09 October 2006




                       Block Listing - Six Monthly Review

Name of Company:                          Hikma Pharmaceuticals PLC

Name of scheme:                           Hikma Pharmaceuticals PLC 2004 Stock
                                          Option Plan

Period of return:              From:      5 April 2006    To:    9 October 2006

Balance under block scheme:               4,058,400 ordinary shares of 10 pence
                                          each

The amount by which the block scheme has  Nil
been increased, if the scheme has been
increased since the date of the last
return:

Number of securities issued/allotted      865,200 ordinary shares of 10 pence each
under scheme during period:

Balance under scheme not yet issued/      3,193,200 ordinary shares of 10 pence
allotted at end of period                 each

Number and class of securities originally 166,537,951 ordinary shares of 10 pence
listed and the date of admission          each originally listed on 1 November 2005

Total number of securities in issue at    167,663,607 ordinary shares of 10 pence
the end of the period                     each


                                    - ENDS -


Enquiries:

Hikma Pharmaceuticals PLC                               [phone]
Henry Knowles, Company Secretary
Susan Ringdal, Investor Relations Director

Notes to Editors


About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange